Victor Villalobos

Victor Villalobos

Johnson & Johnson Co. - New Jersey / United States
Others
AD Scientific Index ID: 4384040
-
person_outline Victor Villalobos's MOST POPULAR ARTICLES
1-) First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancersBI Sikic, N Lakhani, A Patnaik, SA Shah, SR Chandana, D Rasco, ...Journal of Clinical Oncology 37 (12), 946, 20192712019
2-) Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJ Trigo, V Subbiah, B Besse, V Moreno, R López, MA Sala, S Peters, ...The Lancet Oncology 21 (5), 645-654, 20202542020
3-) The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patientsB Alman, S Attia, C Baumgarten, C Benson, JY Blay, S Bonvalot, ...European Journal of Cancer 127, 96-107, 20202472020
4-) Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket studyM Gounder, P Schöffski, RL Jones, M Agulnik, GM Cote, VM Villalobos, ...The Lancet Oncology 21 (11), 1423-1432, 20203152020
5-) NCCN guidelines insights: bone cancer, version 2.2017JS Biermann, W Chow, DR Reed, D Lucas, DR Adkins, M Agulnik, ...Journal of the National Comprehensive Cancer Network 15 (2), 155-167, 20173022017